GILD
Gilead Sciences, Inc
$125.92
1.96 (1.53%) Today
— up— down
Market Cap
$158.77B+13.7%
Revenue (TTM)
$29.44B+3.5%
Net Income (TTM)
$9.13B+55.5%
EPS (TTM)
7.35+55.5%
Shares Out
1.24B
1.24BP/E Ratio
16.98
16.98Forward P/E
31.07
31.07Dividend
$3.22 (2.56%)
$3.22 (2.56%)Ex-Dividend Date
Jun 15, 2026
Jun 15, 2026Open
$128.86
$128.86Previous Close
$127.88
$127.88Day Range
$125.49 – $128.86
$125.49 – $128.8652-Week Range
$107.75 – $157.29
$107.75 – $157.29Beta
0.36
0.36Volume
3.29M
3.29MAvg Volume
6.96M
6.96MAnalyst Rating
Buy
BuyExchange
NASDAQ NMS - GLOBAL MARKET
NASDAQ NMS - GLOBAL MARKETAbout GILD
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy.
Related
News

Gilead Sciences Inc (NASDAQ:GILD): A Sustainable Dividend Leader in the Biotechnology Sector
ChartMill · 6h ago
Gilead (GILD) Moves 3.3% Higher: Will This Strength Last?
Yahoo · 6h ago
Gilead (GILD) Wins FDA Approval for Trodelvy in TNBC
Yahoo · 1d ago
Will Trodelvy’s First-Line TNBC Approval Redefine Gilead Sciences’ (GILD) Oncology-Led Investment Narrative?
Yahoo · 2d ago
Gilead Sciences (GILD) Wins First Line Trodelvy Approval In The US And Europe
Yahoo · 2d ago